Industry NEWS: The GOOD, The BAD, And The UGLY / New Psychedelic Studies, Legalization Bills & MORE!

Hey guys! In this week’s general industry news, we’ll cover some interesting developments. Some are probably going to make some of our viewers turn away from this week’s episode as they discover some pretty “depressing” statistics about North America’s current mental state. However, for those who stick around, you might end up finding that there might be a light at the end of the tunnel as you discover that psilocybin’s benefits might be extended to treat certain Enjoy! Links: Psilocybin & Migraines: https://www.psypost.org/2021/05/a-single-dose-of-psilocybin-has-a-lasting-therapeutic-effect-on-migraine-headache-according-to-a-new-placebo-controlled-study-60793 Increased depression in North America: https://www.meetfieldtrip.com/news/news-details/2021/Canadians-Are-Not-OK-83-of-Canadians-Report-One-Or-More-Symptoms-of-Depression-With-Many-Turning-To-Substances-To-Cope-With-Negative-Emotions-During-COVID-19-Pandemic-According-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx Opioid Overdose In Ontario: https://www.cp24.com/news/opioid-overdose-deaths-up-75-per-cent-in-ontario-during-covid-19-pandemic-new-report-1.5434080 FDA Greenlights Ketamine: https://psychedelicspotlight.com/ketamine-study-parkinsons-disease-treatment/ California Bill to Decriminalize Psychedelics Passes Senate Floor: https://www.marijuanamoment.net/california-bill-to-legalize-possession-of-psychedelics-heads-to-senate-floor-after-committee-action/ Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com Video editing: @themyaholy https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #PsychedelicStocks #PsychedelicIndustry
Psychedelic Business Spotlight: May 21, 2021

Psychedelic Business Spotlight: May 21, 2021

This week in psychedelic business news: Therapists cleared to try MDMA, alternative medicine guru promotes psychedelic therapy, and the Swiss green-light new mescaline study. On the heels of the recently released trial data showing how MDMA-assisted…

MindMed: What Does The Future Hold? ( MMED/ MNMD )

Hey guys! Today, we'll cover Part 2 of our discussion on MindMed's (MMED / MNMD / MMQ) conference call. In the previous episode, we talked about the progress MindMed has made up until this point, MindMed's mission, talent Acquisition, and the progress of their clinical trials. In today's episode, we will take a more futuristic approach and examine the future plans discussed in MindMed's Q1 conference call. We will cover topics such as: A. Where is MindMed going? B. What is MindMed 2.0? C. What will MindMed in 3 years time look like as compared to now? Over the next several years, we expect 4 transformations to occur. 1. MindMed’s transition to a tech company, from a pharmaceuticals company; 2. The shift from classic psychedelics like LSD to “next generation” patent protected substances; 3. Reorientation away from one size fits all medical solutions towards personalized medicine; 4. Finding Partnerships with major pharmaceutical companies. Timestamps: 0:00 - Intro 2:16 - MindMed transitioning to a tech company 7:14 -Next-gen shift 12:11 - Personalized medicine 13:59 - Partnerships Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MNMD #MindMedstock
Shark Tank’s Kevin O’Leary Deep Dives Into Psychedelics

Shark Tank’s Kevin O’Leary Deep Dives Into Psychedelics

Shark Tank investor Kevin O'Leary is a big fan of psychedelics. Here's everything you need to know.

MindMed Conference Call Recap & My THOUGHTS (MMED / MNMD)

Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are: 1. MindMed’s Mission 2. Their Talent acquisition 3. The Progress of their different clinical trials 4. The future Timestamps: 0:00 - Intro 1:59 - MindMed’s Mission 4:36 - MMED’s talent acquisition 7:24 - MindMed’s clinical trial progress 10:48 - Psychiatry department : Project Lucy 14:17 - Addiction department : Project Layla (18MC) 18:33 - Pain department: Project Angie to treat pain card 22:56 - Neurology department: Project Flow using LSD microdosing to treat ADHD 23:43 - MindMed (MMED / MNMD) and its future plans Enjoy! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com Video editing: @themyaholy https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #PsychedelicStocks #MNMD
How to Become a Psychedelic Facilitator

PharmaDrug Launches E-Store Positioned for U.S. Psychedelic Sales

PharmaDrug is bringing an online shop to the U.S. for sales of functional mushrooms and psychedelics once legal.

MindMed Management Update & Earnings Call [ MMED / MNMD / MMQ]

Here’s MindMed's (MMED / MNMD / MMQ) Q1 2021 recorded Earnings call! Soon we will upload a video detailing all the highlights but for now, for those who are interested in listening to the entire call, you can listen to it here! Enjoy! Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedNews #MNMD

New Players, New Studies & Financial Results [MindMed, CMPS, NUMI, TRUFF & WESA]

Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode. Timestamps: 0:00 - Intro 0:18 - FDA clears researchers to test MDMA on themselves 1:55 - MindMed (MMED / MNMD) announces Q1 Financials 4:30 - Compass Pathways (CMPS) announces Q1 Financials 6:56 - Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health 8:17 - Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’ 9:31 - Wesana Health Holdings (WESA) begins trading on the CSE Link to the FDA clearing researchers to test MDMA on themselves: https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/ Link to Mindmed’s Q1 2021 Financial report and business highlights: https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health: https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’: https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/ Link to Wesana Health Holdings (WESA): https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor editing by: @themyaholy Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #PsychedelicStocks #CMPS

How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more

Who's winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now. Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions. Timestamps: 0:00 - Intro 1:34 - What is the clinical trial system? 2:15 - Preclinical 3:00 - Phase 0 3:32 - Phase I 5:45 - Phase II 8:26 - Phase III 10:28 - Phase IV 11:08 - Who's winning the race? 11:16 - MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD 12:02 - Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360 12:28 - MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC) 13:23 - Mydecine (MYCO) and CYBIN (CYBN) following suit Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news! Follow us on social media! 🙌 Instagram: @psychedelicinvestor Email: thepsychedelicinvestor@gmail.com Facebook: @thepsychedelicinvestor editing by: @themyaholy Music: www.bensound.com https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #Numi #CMPS
Business Spotlight

Psychedelic Business News Spotlight: May 14, 2021

This week in psychedelic business news: Therapeutic uses of salvinorin A, a 5-MeO-DMT retreat, and World Boxing Council explores psychedelics.